-
Mashup Score: 0Barbara Eichhorst on CLL Venetoclax and Obinutuzumab With or Without Ibrutinib vs Chemoimmunotherapy - The ASCO Post - 1 year(s) ago
Transcript Disclaimer: This video transcript has not been proofread or edited and may contain errors. This is a phase III trial evaluating frontline treatment in physically fit patients with advanced CLL. 926 were randomized in this study with a standard treatment arm containing chemoimmunotherapy with FCR, chemoimmunotherapy for patients up to the age of 65 years,…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3Educational theme | Latest advances in the treatment for patients with Hodgkin lymphoma - 2 year(s) ago
We highlight the latest advances in the treatment of HL presented at the European Hematology Association (EHA) 2022 Congress.
Source: lymphomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Harry Erba on AML New Data on Quizartinib Plus Standard Chemotherapy - The ASCO Post - 2 year(s) ago
EHA2022 Congress Harry P. Erba, MD, PhD, of Duke Cancer Institute, discusses potentially practice-changing phase III results from the QuANTUM-First trial, which showed that adding quizartinib to standard chemotherapy and up to 3 years of continuation therapy led to improvement in overall survival for adults aged 18 to 75 with newly diagnosed FLT3-ITD–positive acute myeloid…
Source: ascopost.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @ASCOPost: Harry P. Erba, MD, PhD, on AML: New Data on Quizartinib Plus Standard Chemotherapy https://t.co/XIDqTAAUB9 #leusm #leukemia #…
-
-
Mashup Score: 0Anna Sureda on Large B-Cell Lymphoma New Data on Axicabtagene Ciloleucel vs Standard of Care - The ASCO Post - 2 year(s) ago
EHA2022 Congress Anna Sureda, MD, PhD, of the University of Barcelona and the Catalan Institute of Oncology, discusses phase III clinical and patient-reported outcomes from the ZUMA-7 trial, which showed that axicabtagene ciloleucel was superior to second-line standard-of-care treatment in patients 65 years or older with relapsed or refractory large B-cell lymphoma (Abstract…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Robin Foà , MD, Sapienza University of Rome, Rome, Italy, discusses opportunities for a chemotherapy-free frontline induction treatment for patients with…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0The potential of CAR T-cell therapy in combination with antibodies for the treatment of ALL - 2 year(s) ago
In this video, Sara Ghorashian, PhD, MD, FRCP, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK talks…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0The measurement of molecular biomarkers to aid CLL treatment - 2 year(s) ago
Paul Hampel, MD, Mayo Clinic, Rochester, MN, talks on the incorporation of molecular biomarkers in the treatment and management of…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Emerging strategies to manage kidney disease in SCD patients - 2 year(s) ago
In this video, Santosh Saraf, MD, University of Illinois Hospital, Chicago, IL, briefly discusses strategies to manage kidney disease in…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Quizartinib, decitabine, and venetoclax combination therapy in patients with AML and prior exposure to FLT3 inhibitors. - 2 year(s) ago
During the European Hematology Association (EHA) 2022 Congress, the triplet combination of quizartinib, a FLT3 inhibitor, with decitabine and venetoclax in patients with FLT3-ITD-mutated acute myeloid leukemia (AML) was evaluated.
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1The impact of RBPs in the development of hematological malignancies and bone marrow failure - 2 year(s) ago
Miguel Gallardo, PhD, Spanish National Cancer Research Center (CNIO), Madrid, Spain, discusses the impact of RNA binding proteins (RBPs) in…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Barbara Eichhorst, MD, on CLL: Venetoclax and Obinutuzumab With or Without Ibrutinib vs Chemoimmunotherapy https://t.co/jhX0KWogYC #EHA22 #EHA2022 #leusm #CLL #leukemia #hematology #immunotherapy @UniCologne